Discovers, develops and intend to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders. Product candidates will target insomnia, anxiety, depression, cancer, diabetes, and multiple sclerosis.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Steadily improving financial results, as in less and less losses. Then in quarter three, we earn nearly half of the share price in one quarter. According to Larry D. Spears of Money Morning:
"NBIX concentrates on neurological and endocrine-related diseases and has eight products in various phases of development and testing. The company has just begun generating revenues from two of its therapies, including one for type 2 diabetes, America's number one growth disease. Revenue of $32.9 million is expected for 2010, with growth to $68.8 million, and NBIX posted its first-ever profit of $3.33 a share in the third quarter. What makes it most interesting, however, are its "pipeline partnerships" with Abbott Labs in men's and women's health, GlaxoSmithKine (GSK) in anxiety and depression treatment, and Boehringer Ingelheim Chemicals for diabetes - assuring NBIX of needed funding and ample future marketing help."